Hot Features
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocor... Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -2.57 | -8.12776723593 | 31.62 | 31.955 | 26.66 | 449242 | 28.64855189 | CS |
| 4 | -1.88 | -6.07824118978 | 30.93 | 35.66 | 26.66 | 421089 | 31.05307824 | CS |
| 12 | 10.05 | 52.8947368421 | 19 | 35.66 | 18.5 | 432579 | 26.96169039 | CS |
| 26 | 12.35 | 73.9520958084 | 16.7 | 35.66 | 14.27 | 334288 | 22.83899497 | CS |
| 52 | 12.11 | 71.4876033058 | 16.94 | 35.66 | 13.085 | 355005 | 19.41773806 | CS |
| 156 | 25.14 | 642.966751918 | 3.91 | 35.66 | 2.42 | 245052 | 13.97238717 | CS |
| 260 | 22.82 | 366.292134831 | 6.23 | 35.66 | 1.95 | 232497 | 10.59129968 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.